TriLink BioTechnologies to relocate to expand operations

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/BackyardProduction)
(Image: Getty/BackyardProduction)

Related tags: operations, facility, Research, Research and development

TriLink BioTechnologies, a subsidiary of Maravai, that provides gene therapy services to researchers, has announced it will relocate to expand the company’s operations.

The company signed a lease on a new facility in Sorrento Valley near San Diego, California. The lease includes an option to expand further dependent on future growth.

David Weber, chief commercial officer of Maravai, told us that the main driver behind this relocation was the demand for product outpacing the company’s current capacity. “It’s pretty simple, we’re just wearing a pair of pants that are too tight, and when I say demand I mean demand for nucleic acid, DNA and RNA, complex products,”​ Weber explained.

Per the expansion, the company’s current good manufacturing practice (cGMP) production capabilities will be relocated, which Weber told us are also in high demand because of the number of gene therapy and nucleic acid-based treatments entering into Phase I and II clinical trials.

“All of those are at the forefront today and have a lot of visibility and initial success and potential future success, in terms of impacting human health,”​ Weber said.

The new facility can accommodate growth to more than 350 R&D, commercial and manufacturing employees from the company’s current 150 employees. Weber told us, “We expect employee growth to continue and, assuming demand continues at the pace of growth as it is now, we will likely have to take more space to accommodate more lab space, as well as more people.”

TriLink will move into half of the 180,000-square-foot building in the fall of 2019, with the relocation completed by the end of the year. Maravai told us that its growth has been occurring rapidly since the company acquired TriLink and made investments in it beginning in August 2016.

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more